Foresite Capital Management IV, LLC Diversified Active

CIK: 0001704132 · Show all filings

Period: Q4 2021 (← Previous) (Next →)

Filing Date: Feb 11, 2022

Total Value ($000): $486,015 (100.0% shares, 0.0% debt)

Holdings (9)

— Kinnate Biopharma Inc. 35.3%

Value ($000) $171,382 Shares 9,671,643 Est. Cost $39.78 Unrealized —

— Lyell Immunopharma, Inc. 21.2%

Value ($000) $102,804 Shares 13,282,181 Est. Cost $16.24 Unrealized —

ACRS Aclaris Therapeutics, Inc. 10.2%

Value ($000) $49,422 Shares 3,399,034 Est. Cost $15.18 Unrealized -0.2%

PHVS Pharvaris N.V. 9.7%

Value ($000) $46,939 Shares 3,261,926 Est. Cost $31.46 Unrealized -50.3%

QSI Quantum-Si Incorporated 7.2%

Value ($000) $35,129 Shares 4,463,619 Est. Cost $10.48 Unrealized -28.1%

NRIX Nurix Therapeutics, Inc. 7.2%

Value ($000) $34,908 Shares 1,205,798 Est. Cost $25.20 Unrealized +20.3%

KURA Kura Oncology, Inc. 5.3%

Value ($000) $25,899 Shares 1,849,947 Est. Cost $20.39 Unrealized -20.5%

HLTHQ Cue Health Inc. 2.8%

Value ($000) $13,492 Shares 1,006,089 Est. Cost $11.81 Unrealized —

— Cymabay Therapeutics, Inc. 1.2%

Value ($000) $6,040 Shares 1,787,094 Est. Cost $3.49 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Kinnate Biopharma Inc.	9,671,643	$171,382	35.3%	$39.78	—	COM	49705R105
—	Lyell Immunopharma, Inc.	13,282,181	$102,804	21.2%	$16.24	—	COM	55083R104
ACRS	Aclaris Therapeutics, Inc.	3,399,034	$49,422	10.2%	$15.18	-0.2%	COM	00461U105
PHVS	Pharvaris N.V.	3,261,926	$46,939	9.7%	$31.46	-50.3%	COM	N69605108
QSI	Quantum-Si Incorporated	4,463,619	$35,129	7.2%	$10.48	-28.1%	COM CL A	74765K105
NRIX	Nurix Therapeutics, Inc.	1,205,798	$34,908	7.2%	$25.20	+20.3%	COM	67080M103
KURA	Kura Oncology, Inc.	1,849,947	$25,899	5.3%	$20.39	-20.5%	COM	50127T109
HLTHQ	Cue Health Inc.	1,006,089	$13,492	2.8%	$11.81	—	COM	229790100
—	Cymabay Therapeutics, Inc.	1,787,094	$6,040	1.2%	$3.49	—	COM	23257D103